莱特莫韦

Description

Letermovir · CAS 917389-32-3 · C29H28F4N4O4. UNII 1H09Y5WO1F.

Identification

CAS Registry Number	917389-32-3
PubChem CID	45138674
Molecular formula	C29H28F4N4O4
IUPAC name	2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
UNII (FDA)	1H09Y5WO1F

Computed Descriptors

Molecular Weight	572.5
XLogP3	4.6
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	7
Exact Mass	572.20466804
Monoisotopic Mass	572.20466804
Topological Polar Surface Area	77.8
Heavy Atom Count	41
Formal Charge	0

Physical description & handling notes

• Letermovir inhibits the activity of the DNA terminase complex of CMV thereby preventing the cutting of viral DNA into mature length genomes for packaging into viral particles. Letemovir inhibits the DNA terminase complex with an EC50 of 2.1nM.

GHS Hazard Classification

Reported hazard statements	H361 (97.2%), H373 (100%)

Documented Uses

• Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in recipients, ≥6 months of age and ≥6 kg, of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in kidney transplant recipients, ≥12 years of age and ≥40 kg, who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegative).
• Letermovir is an antiviral agent which targets the DNA terminal transferase complex of the cytomegalovirus (CMV) and which is used to prevent CMV reactivation in immunocompromised patients. Letermovir has been associated with mild-to-moderate serum aminotransferase elevations during therapy but has not been linked to cases of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Anti-Infective Agents; Antiviral Agents;
• Avoid St. John's Wort. Co-administration may lead to decreased serum concentrations of letermovir.
• Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
• Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.

Synonyms

Letermovir; 917389-32-3; Prevymis; AIC246; AIC-246; AIC 246; MK-8228; 1H09Y5WO1F; DTXSID40238683; letermovirum; RefChem:57199; DTXCID90161174; J05AX18; 805-689-9; UNII-1H09Y5WO1F; MFCD22572725

Frequently Asked Questions

What are the CAS number and molecular formula of Letermovir?

CAS 917389-32-3; molecular formula C29H28F4N4O4; molecular weight — g/mol.

What other names is Letermovir known by?

Letermovir, 917389-32-3, Prevymis, AIC246, AIC-246, AIC 246.

Is Letermovir classified as hazardous?

Hazard statements reported: H361, H373.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.